WILLIAM PEACOCK to Venous Thromboembolism
This is a "connection" page, showing publications WILLIAM PEACOCK has written about Venous Thromboembolism.
Connection Strength
1.327
-
Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design. Acad Emerg Med. 2016 11; 23(11):1280-1286.
Score: 0.412
-
Target-specific Oral Anticoagulants in the Emergency Department. J Emerg Med. 2016 Feb; 50(2):246-57.
Score: 0.386
-
D-dimer Levels in Acute, Medically Ill, Hospitalized Patients: A Large, Prospective, Multicenter Study in the United States. Clin Appl Thromb Hemost. 2025 Jan-Dec; 31:10760296251320406.
Score: 0.182
-
Benefit of early discharge among patients with low-risk pulmonary embolism. PLoS One. 2017; 12(10):e0185022.
Score: 0.110
-
External validation of a multivariable claims-based rule for predicting in-hospital mortality and 30-day post-pulmonary embolism complications. BMC Health Serv Res. 2016 10 22; 16(1):610.
Score: 0.103
-
Venous thromboembolism prophylaxis in hospitalized heart failure patients. J Card Fail. 2008 Mar; 14(2):127-32.
Score: 0.057
-
Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. Clin Ther. 2017 Jul; 39(7):1426-1436.e2.
Score: 0.027
-
Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. Int J Clin Pract. 2017 Jan; 71(1).
Score: 0.026
-
Outcomes related to variation in hospital pulmonary embolus observation stay utilization. Hosp Pract (1995). 2016 Aug; 44(3):133-7.
Score: 0.025